Troriluzole

Posted results on ClinicalTrials.gov for NCT04693351

• Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement) (score on a scale)
  • Troriluzole vs Placebo: Least squares mean difference 0.97 (95% CI 0.02 to 1.92), p-value 0.041, Mixed Models Analysis, superiority

Serious adverse events (For Adverse Events: From first dose up to approximately 12 weeks For All-cause Mortality: From Day 1 up to approximately 12 weeks): Troriluzole 3 of 292; Placebo 2 of 289

Source: ClinicalTrials.gov results for NCT04693351 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for NCT03701399

• Randomization Phase: Change From Baseline in the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Total Score at Week 48 in SCA Participants (score on a scale)
  • Troriluzole vs Placebo: Least squares mean difference -0.06 (95% CI -0.47 to 0.34), p-value 0.7581, Mixed Models Analysis, superiority
  • Troriluzole vs Placebo: Least square mean difference -0.56 (95% CI -1.11 to -0.01), p-value 0.0450, Mixed Models Analysis, superiority

Serious adverse events (For Adverse events (AEs): From first dose of study drug up to Week 48 plus 30 days (maximum duration: 52 weeks) For All-cause mortality: From randomization up to Week 48 plus 30 days (maximum duration: 52 weeks)): Troriluzole 6 of 108; Placebo 8 of 109

Source: ClinicalTrials.gov results for NCT03701399 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for NCT03299166

• Change From Baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total Score (Scores on a scale)
  • Troriluzole - Randomization Phase vs Placebo - Randomization Phase: LS Mean Difference -1.00 (95% CI -2.59 to 0.60), p-value 0.2202, Mixed Models Analysis, superiority

Serious adverse events (Randomization Phase: Maximum duration: 12 weeks): Troriluzole - Randomization Phase 0 of 122; Placebo - Randomization Phase 0 of 122

Source: ClinicalTrials.gov results for NCT03299166 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for NCT02960893

• Change From Baseline in Total Score on the Scale for the Assessment and Rating of Ataxia (SARA) at Randomization Phase Week 8 (score on a scale)
  • Troriluzole - Randomization Phase vs Placebo - Randomization Phase: LS Mean 0.2 (95% CI -0.5 to 0.9), p-value 0.519, Mixed Model with Repeated Measures, superiority

Serious adverse events (From first dose of study drug to 30 days post the last dose in the OLE Phase (Up to 348 weeks after last randomization participant was enrolled)): Troriluzole - Randomization Phase 4 of 71; Placebo - Randomization Phase 1 of 70; Troriluzole/Troriluzole - OLE Phase 11 of 64; Placebo/Troriluzole - OLE Phase 9 of 67

Source: ClinicalTrials.gov results for NCT02960893 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.